XRCC5 and Miyoshi myopathy: A study on MM patients treated with thalidomide also revealed that those with specific gene polymorphisms in ERCC1, ERCC5, or XRCC5 (KU80) had higher response rates with longer overall survival being associated with polymorphisms in ERCC1 and XRCC5.